The headquarters of the IBSA Institut Biochimique SA Group is in Switzerland, in the Pian Scairolo CorPharma district, the sustainable industrial quarter located between the municipalities of Lugano and Collina d’Oro, where the company’s headquarters is also located.
Each site is dedicated to specific manufacturing lines, in compliance with the principle of separation of production processes: a strategy that allowed the company to be certified by the most stringent Regulatory Authorities, as shown by the recent approval of IBSA products in the United States.
The cosmos plant
With a total area of 16,200 m2, equal to three football fields, cosmos is IBSA’s largest production plant. Completely renovated and inaugurated in 2022, the building is characterised by absolute modernity, with production lines managed by technologically advanced, automated and interconnected systems, according to the most recent 4.0 industry requirements, capable of ensuring a precise control of the plants and the production processes, as well as the highest quality standards of the drugs manufactured. Efficiency and optimization, quality and precision guide the activity of the plant, which includes 3 production lines that started at full capacity at the beginning of 2022 with the production of thyroid hormones.
The Lamone Plant in the Canton of Ticino, Switzerland
The Lamone plant produces for the entire IBSA Group gonadotropins and progesterone, hormones used in Assisted Reproductive Technology (ART) techniques, an area of particular importance for both the pharmaceutical sector and the company, which today has become one of the world’s largest operators. In fact, IBSA developed dedicated plants and patented an exclusive purification process for human gonadotropins. Furthermore, thanks to its highly innovative research and development, the company has marketed the only formulation of progesterone in aqueous solution, which can be administered subcutaneously, thus responding to the goal of improving local tolerability, facilitating administration and increasing patient compliance.
The plant is an example of IBSA’s strategic choice to develop and manufacture entirely in-house products, with innovative and patient-friendly formulations. Indeed, all processing aspects – from purification to finished product, from quality controls to packaging – are concentrated in this manufacturing site. The latter occupies a total area of 4,700 m2 and employs 104 people. The site directly supplies several markets all over the world, including – in addition to Italy – Switzerland, Europe, South Africa, South America, the Middle East and Asia.
The Manno plant in the Canton of Ticino, Switzerland
The Manno production site specialises in the production of thyroid hormones in two pharmaceutical forms: soft gel capsules and multi- and single-dose liquid oral solutions. The advantages of soft gels are high dosing precision, greater bioavailability and greater stability, while liquid oral solutions of levothyroxine are dispensed in single-dose strips that are easy to use even by subjects with swallowing difficulties or dysphagia, such as children or the elderly, thus offering the benefit of ensuring the delivery of precise drug doses. The production site in Manno occupies an area of 3,950 m2 and employs 166 people between Production, Quality Assurance and Quality Control, Technical Maintenance and Warehouse Services. The production of the plant serves the entire IBSA Group and directly supplies markets such as Switzerland, Europe and the United States.
The Collina D’oro plant in the Canton of Ticino, Switzerland
The Collina d'Oro production site produces and packages several pharmaceutical forms – such as syrups, creams and ointments in tube, oral liquids in stick, granular powders in sachet, tablets and hard gelatin capsules in blister – for therapeutic solutions in the osteoarticular, pain and inflammation, respiratory, urological, cardio-metabolic and aesthetic medicine areas.
The plant has an area of 3,600 m2 and employs 84 people on 13 different production lines.
